AxoGen, Inc.
NASDAQ:AXGNMedical - Devices
+$0.25 today
- Market cap
- $3.40B
- Beta
- 1.12
- P/E (TTM)
- -73.4
- EPS (TTM)
- -$0.61
Volume 2.11M
Average 1.08M
AXGN Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
AxoGen, Inc.NASDAQ: AXGN
Depreciation & Amortization · Q3 FY2026 · quarter ended Sep 2026
Depreciation & amortization dips below year-ago levels
Q3 FY2026 depreciation & amortization of $1.69M fell 8.0% year over year, behind the +19.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 21.3% from the prior quarter. Over 3 fiscal years it compounded at +19.1% a year.
Context
- Depreciation & amortization amounted to 3.6% of revenue in FY2025, down 0.5 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -8.0% toward the trailing-twelve-month pace of +19.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 8.19M USD
- Year-over-year change
- +4.5%
- 4-year CAGR
- +14.7%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.19M | +4.5% |
| FY2024 | 2024-12-31 | 7.84M | +41.1% |
| FY2023 | 2023-12-31 | 5.55M | +14.4% |
| FY2022 | 2022-12-31 | 4.85M | +2.4% |
| FY2021 | 2021-12-31 | 4.74M | — |
Depreciation & Amortization vs competitors
How AXGN compares with its peers on the latest reported figures
- AXGN's LTM Sep 2026 depreciation & amortization of $8.91M is the 3rd largest of the 7 companies compared; the peer median is $5.77M.
- Its year-over-year change of +19.5% is the 4th highest of 7, against a peer median of +21.7%.
- Depreciation & amortization amounts to 3.3% of revenue for AXGN, versus a peer median of 4.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $30.95M | +45.2% | +35.9% | 6.0% | |
| LTM Mar 2026 | $16.5M | +94.2% | +54.4% | 4.2% | |
| LTM Sep 2026 | $8.91M | +19.5% | +19.1% | 3.3% | |
| LTM Mar 2026 | $6.86M | +34.4% | -13.4% | 340.1% | |
| LTM Mar 2026 | $4.68M | +9.1% | +59.3% | 3.8% | |
| LTM Jun 2026 | $1M | -5.9% | -5.2% | 1.3% | |
| LTM Jun 2026 | $384.08K | -31.7% | +16.1% | — | |
| Peer median (excluding AXGN) | $5.77M | +21.7% | +26.0% | 4.2% | |
Competitors are the stored peer set for AXGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (26.99M) | (28.95M) | (21.72M) | (9.96M) | (15.7M) |
| Depreciation & Amortization | 4.74M | 4.85M | 5.55M | 7.84M | 8.19M |
| Deferred Income Tax | 3.37M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 10.92M | 15.59M | 14.42M | 15.91M | 30.11M |
| Change in Working Capital | (6.28M) | (9.56M) | (4.39M) | (10.04M) | (24.62M) |
| Accounts Receivables | (499K) | (4.64M) | (2.69M) | 392K | (2.46M) |
| Inventory | (7.48M) | (3.66M) | (6.05M) | (10.16M) | (9.19M) |
| Accounts Payables | (270K) | 660K | 6.51M | 125K | (7.16M) |
| Other Working Capital | 1.97M | (1.93M) | (2.15M) | (399K) | (5.81M) |
| Other Non-Cash Items | 831K | 2M | 415K | 797K | 2.83M |
| Operating Cash Flow | (13.41M) | (16.07M) | (5.72M) | 4.54M | 812K |
| Capital Expenditures | (28.4M) | (21.25M) | (14.92M) | (4.52M) | (3.75M) |
| Acquisitions (Net) | (589K) | 3.2M | 0 | 0 | 0 |
| Purchases of Investments | (68.7M) | (39.25M) | (10.2M) | (5.77M) | (13.72M) |
| Sales of Investments | 72.5M | 57.3M | 44.37M | 0 | 14M |
| Other Investing Activities | 1.54M | (3.2M) | (1.05M) | (1.42M) | (1.85M) |
| Investing Cash Flow | (23.65M) | (3.2M) | 19.25M | (10.3M) | (5.32M) |
| Debt Repayment | 14.99M | (12K) | (10K) | (10K) | (32K) |
| Common Stock Issued | 5.47M | 1.81M | 1.96M | 2.3M | 10.53M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 20.45M | 1.79M | 1.95M | 2.29M | 10.5M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (16.6M) | (17.47M) | 15.49M | (3.47M) | 5.99M |
| Free Cash Flow | (41.81M) | (37.32M) | (20.63M) | 11K | (2.93M) |
AxoGen, Inc.
NASDAQ:AXGN
Intrinsic Alpha fair value
Locked
Current Price
$56.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.